{"id":386195,"date":"2020-11-20T16:08:18","date_gmt":"2020-11-20T21:08:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386195"},"modified":"2020-11-20T16:08:18","modified_gmt":"2020-11-20T21:08:18","slug":"bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/","title":{"rendered":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V."},"content":{"rendered":"

<\/p>\n

Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.<\/b><\/p>\n

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE<\/a>)–Bicycle Therapeutics plc<\/a> (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae<\/i>) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle\u2019s use of Pepscan\u2019s CLIPS peptide technology.\n<\/p>\n

\nThe companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay \u20ac3 million upfront, will pay \u20ac1 million on the first anniversary of the date of settlement, and will make potential additional payments to Pepscan based on achievement of specified clinical, regulatory and commercial milestones.\n<\/p>\n

About Bicycle Therapeutics<\/b><\/p>\n

\nBicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles<\/i>\u00ae, for diseases that are underserved by existing therapeutics. Bicycles<\/i> are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles<\/i> attractive candidates for drug development. Bicycle\u2019s lead product candidate, BT1718, a Bicycle<\/i> Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I\/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I\/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I\/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cforecasts,\u201d \u201cgoal,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cseeks,\u201d \u201cwill\u201d and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle\u2019s use of CLIPS peptide technology in the development of its product candidates BT1718 and THR-149, Bicycle\u2019s future payment obligations to Pepscan, and Bicycle\u2019s contemplated achievement of specified clinical, regulatory and commercial milestones. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle\u2019s abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials by Bicycle or its collaboration partners and in the clinical development of Bicycle\u2019s product candidates; availability and timing of results from clinical trials; expectations for regulatory approvals to conduct trials or to market product; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled \u201cRisk Factors\u201d in Bicycle\u2019s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201120005685\/en\/<\/a><\/span><\/p>\n

Investor and Media Contact:
\n<\/b>
Argot Partners
\n
Maeve Conneighton or Eleanor Barisser
\n
bicycle@argotpartners.com
\n<\/a>
+1-212-600-1902\n<\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Health FDA Legal Clinical Trials Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle\u2019s use of Pepscan\u2019s CLIPS peptide technology. The companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay \u20ac3 million upfront, will pay \u20ac1 million on the first anniversary of the date of settlement, … <\/p>\n

Continue reading “Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386195","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle\u2019s use of Pepscan\u2019s CLIPS peptide technology. The companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay \u20ac3 million upfront, will pay \u20ac1 million on the first anniversary of the date of settlement, … Continue reading "Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-20T21:08:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.\",\"datePublished\":\"2020-11-20T21:08:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/\"},\"wordCount\":734,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/\",\"name\":\"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-20T21:08:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/","og_locale":"en_US","og_type":"article","og_title":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. - Market Newsdesk","og_description":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle\u00ae) technology, today announced that it has entered into a settlement and license agreement with Pepscan Systems B.V. regarding Bicycle\u2019s use of Pepscan\u2019s CLIPS peptide technology. The companies have agreed to settle all intellectual property disputes worldwide. Under the terms of the settlement, Bicycle has been granted a license to use CLIPS peptide technology in the development of its product candidates BT1718 and THR-149. Bicycle will pay \u20ac3 million upfront, will pay \u20ac1 million on the first anniversary of the date of settlement, … Continue reading \"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-20T21:08:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.","datePublished":"2020-11-20T21:08:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/"},"wordCount":734,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/","name":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-20T21:08:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201120005685r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicycle-therapeutics-announces-settlement-of-patent-dispute-with-pepscan-systems-b-v\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386195"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}